Article

The likelihood of heterogeneity or additional mutation in KRAS or associated oncogenes to compromise targeting of oncogenic KRAS G12C

2017-06-13

Abstract excerpt

Activating mutations in RAS genes are associated with approximately 20% of all human cancers. New targeted therapies show preclinical promise in inhibiting the KRAS G12C variant, however, concerns exist regarding the effectiveness of such therapies in vivo given the possibilities of existing intratumor heterogeneity or de novo mutation leading to treatment resistance. We performed deep sequencing of 27 KRAS G12...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 63227e1b-54ca-535c-8c4d-86292a9e6b4d
DOI: 10.1101/149724

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The likelihood of heterogeneity or additional mutation in KRAS or associated oncogenes to compromise targeting of oncogenic KRAS G12CDOI 10.1101/149724Read

Heterogeneity and mutation in KRAS and associated oncogenes: evaluating the potential for the evolution of resistance to targeting of KRAS G12C.Semantic proximity Read

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.Semantic proximity Read

Acquired Resistance to KRASG12C Inhibition in Cancer.Semantic proximity Read

Resistance looms for KRAS G12C inhibitors and rational tackling strategies.Semantic proximity Read

A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors.Semantic proximity Read

More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C.Semantic proximity Read

The Abundance of KRAS and RAS Gene Mutations in Cancer.Semantic proximity Read

Diverse alterations associated with resistance to KRAS(G12C) inhibition.Semantic proximity Read

A Nexus between Genetic and Non-Genetic Mechanisms Guides KRAS Inhibitor Resistance in Lung Cancer.Semantic proximity Read

Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.Semantic proximity Read

Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancerSemantic proximity Read

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies.Semantic proximity Read